FATE THERAPEUTICS INC — Director's Dealing 2020

Dec 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: FATE THERAPEUTICS INC (FATE)
CIK: 0001434316
Period of Report: 2020-12-17

Reporting Person: Wolchko J Scott (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-17	Common stock	M	20000	$6.62	Acquired	439969	Direct
2020-12-17	Common stock	S	3168	$90.9813	Disposed	436801	Direct
2020-12-17	Common stock	S	13936	$91.7705	Disposed	422865	Direct
2020-12-17	Common stock	S	2796	$92.9418	Disposed	420069	Direct
2020-12-17	Common stock	S	100	$93.44	Disposed	419969	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-17	Stock Option (right to buy)	$6.62	M	20000	Disposed	2024-01-08	Common Stock (20000)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.

F2: Represents the weighted average sale price of the shares sold ranging from $90.41 to $91.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

F3: Represents the weighted average sale price of the shares sold ranging from $91.41 to $92.36 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

F4: Represents the weighted average sale price of the shares sold ranging from $92.43 to $93.35 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

F5: This option is fully vested.

F6: Not applicable.